

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

ARA-290 has shown small-fiber repair signals in human neuropathy trials and tissue-protective, metabolic, and cardiac effects in animal models; broader human healthspan benefits are plausible but unproven [4,8,13]. ARA-290 (cibinetide) is an experimental 11-amino-acid peptide modeled on the tissue-protective surface of erythropoietin (EPO) [1]. Its proposed innate repair receptor (IRR), an EPOR/CD131 complex, links cellular stress responses to anti-inflammatory and pro-survival signaling [2]. The peptide was designed to separate these actions from erythropoiesis, and short human trials have not shown an erythropoietic signal [1,3]. Its clinical effects remain outcome- and population-specific, and the proposed experimental healthspan schedule is speculative.

 Short-term tolerability is generally favorable in the studied populations, but potentially related serious events occurred; longer-term safety is unknown [5,6,10].

★★ Probably promotes small-fiber repair under some studied neuropathy conditions; consistent pain relief and lasting functional benefit remain unestablished [4,6].

★ Plausible for human healthspan benefit [8,13].

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

Human safety evidence comes mainly from small 28-day neuropathy studies and a 12-week eye study that enrolled nine participants, eight of whom completed treatment [3,4,5,6,10]. Serious events judged possibly related occurred in the diabetes and dose-ranging sarcoidosis trials [5,6].

Evidence for efficacy is promising, preliminary, and outcome-specific. Small randomized studies reported symptom and nerve-imaging improvements, but pain and functional outcomes did not consistently separate from placebo [3,4,5,6]. Corneal imaging is a structural surrogate, but is not equivalent to prevention of disability or sustained restoration of function.

Dose Used In Trials

Human neuropathy studies used 2 mg intravenously (IV) three times weekly for four weeks and 4 mg subcutaneously (SC) daily for 28 days [3,4,5]. A sarcoidosis dose-ranging trial compared 1, 4, and 8 mg SC daily for 28 days with placebo [6]. The 4 mg regimen has the clearest controlled signal for corneal nerve fiber area in sarcoidosis [6].

The reported terminal plasma half-life after 4 mg SC is approximately 20 minutes [4,5].

The experimental neuropathy regimen with the strongest controlled structural signal in the cited dose-ranging trial is:

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

• 4 mg SC daily for 28 days

In the 64-participant dose-ranging trial, only 4 mg/day significantly improved the primary corneal nerve fiber area endpoint versus placebo; 1 and 8 mg did not. Regenerating skin-fiber length also increased at 4 mg. Pain and six-minute walk comparisons did not achieve statistical significance [6].

Healthspan Dose

Cell and animal studies support IRR-associated repair signaling [1,2,7,8,9]. Receptor expression, tissue access, injury state, and the measured endpoint can all affect interpretation.

Mechanistic considerations:

- IRR-associated signaling is biologically plausible at transient exposures [1,2].
- Downstream effects can outlast circulating peptide in experimental systems [7,14].

Lower intermittent doses are a speculative experimental possibility. Published human pharmacokinetic data are limited but include measured exposure after 4 mg SC and 2 mg IV. [4].

Based on *in vitro* work:

- **Plausible receptor engagement** was found at “**sub- to low-nM.**”
- **Plausible functional activation window** was found at “**~0.1 nM to a few tens of nM**” for endpoints like angiogenesis, anti-inflammatory gene programs.

The target tissue type should be taken into consideration when making dose decisions. For example, **disc endplate and nucleus pulposus** are relatively poorly perfused; extrapolating from non-ARA-290 PK, **interstitial concentrations** there will be lower than plasma and may require **2–10×** plasma overshoot to reach robust functional levels.

Lower intermittent doses might engage IRR signaling, but human PK/PD data do not establish a minimum effective dose for healthspan or chronic tissue protection. Extrapolating from mechanistic biology, plausible maintenance / longevity doses

- **0.5 mg SC overlaps the lower functional window; likely sufficient to *transiently* engage receptor signaling in well-perfused tissues and may trigger downstream signaling in some cell types.** For poorly perfused targets, this may be marginal after accounting for tissue access loss.
- **1 mg sits squarely within the lower–mid functional activation window; likely to produce a stronger and more reliable receptor engagement** signal systemically and in many tissues.
- **2.0 mg** provides a larger margin
- **4.0 mg** matches the daily neuropathy dose

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

Mechanistically, **all three low doses plausibly reach the repair-cascade activation window**, with larger doses offering more certainty to account for incorrect assumptions in our mechanistically extrapolated PK data, and a stronger buffer against variability in tissue penetration.

The following table summarizes the evidence relevant to six proposed tissue targets. Human concentration thresholds and preventive dosing frequencies have not been established for any of tissue that might plausibly benefit from ARA-290 in the context of healthspan, their sensitivity / resistance to plasma concentration, and an extrapolation of the optimal application frequency based on the tissues' turnover, ongoing low-grade stress, etc. This extrapolation is speculative.

Tissue	Sensitivity to ARA-290 plasma concentration	Likely need for exposure frequency
Small-fiber peripheral nerves (sensory/autonomic)	High ; IRR upregulation on stressed small fibers; effects seen at sub- to low nM in vitro.	Daily or every-other-day ; repeated pulses support ongoing repair and symptom control.
Microvascular endothelium	High-moderate ; endothelial cytoprotection and anti-inflammatory signaling activated at low nM .	Every-other-day to weekly ; frequent pulses help maintain endothelial resilience but may tolerate spacing.
Immune cells / tissue macrophages	Moderate ; macrophage M1→M2 shifts and cytokine suppression occur in sub- to low nM ranges.	Every-other-day ; periodic engagement reduces chronic inflammation while limiting desensitization.
Cardiac myocardium	Moderate ; cardioprotective signaling observed in preclinical models at low nM exposures.	Every-other-day to weekly ; intermittent pulses likely sufficient for stress-resilience effects.
Central nervous system glia (microglia)	Moderate-low ; anti-inflammatory effects reported at low nM but CNS access is limited.	Weekly or pulsed courses ; less frequent dosing may suffice due to slower CNS kinetics and tissue access limits.
Pancreatic islets and metabolic tissues	Low-moderate ; preliminary signals for β -cell protection at low nM but evidence is limited.	Every-other-day to weekly ; conservative, intermittent exposure until stronger clinical data exist.

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

Because some tissues which benefit most from frequent dosing activate at lower plasma saturation levels, while several other tissues which need higher plasma concentration need less frequent dosing, the following is a hypothetical longevity dosing strategy.

- **4 mg SC Monday, 2 mg SC Wednesday, 2 mg SC Friday**

This 4/2/2 mg schedule totals 8 mg weekly, or 32 mg over four weeks.

Benefits

- **Neuropathic symptoms:** improvement is possible in selected patients, but controlled pain results are mixed. Symptom-scale changes should not be generalized to reliable analgesia [3,4,5,6].
- **Small-fiber repair:** corneal and regenerating skin-fiber findings support a probable biological repair effect under some studied conditions, with uncertainty about durability and patient-important benefit [4,6].
- **Longer-term nerve preservation and autonomic benefit:** plausible from repair biology, but prevention of progressive nerve loss has not been demonstrated in a long-term controlled human study [3,4,5,6].
- **Anti-inflammatory and cytoprotective activity:** observed in cellular and animal injury models, including inflammatory neuropathy; human systemic effects cannot be inferred directly from these mechanisms [1,2,9,15].
- **Neuroinflammation:** rat nerve-injury experiments linked reduced allodynia to suppression of spinal microglial responses [14]. An Alzheimer-like mouse study implicated patrolling monocytes, with diminished effects in the later disease setting [11]. Sustained human cognitive benefit remains speculative.
- **Microvascular and repair effects:** biologically plausible from experimental tissue-protection findings [1,2]. The small open-label diabetic macular edema study did not improve mean visual acuity or retinal thickness, so it does not establish a general human microvascular benefit [10].
- **Cardioprotection:** a long-duration aging-rat experiment reported preservation of cardiac function, reduced inflammation, and improved mitochondrial stress resistance [13]. Corresponding human benefits are plausible, not established.
- **Metabolic effects:** preliminary human changes in glycemic and lipid markers and improved insulin secretion in diabetic rats support a possible metabolic benefit [5,8]. They do not establish prevention of diabetes or its complications.

Investigated Applications

- Sarcoidosis-associated small-fiber neuropathy — small randomized human trials, with structural repair signals and mixed symptom outcomes [3,4,6].

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

- Type 2 diabetes with neuropathic symptoms — preliminary controlled human evidence; neither disease modification nor durable complication prevention is established [5].
- Other nerve-injury or inflammatory neuropathies — animal evidence supports further investigation, including experimental autoimmune neuritis [7,9,14,15].

Precautions

- **Hematologic and immunological context:** short trials did not show erythropoiesis, but this does not establish safety in complex blood disorders or during combination treatment [3,4,5,6]. The eye study excluded erythropoiesis-stimulating agents; an exclusion is not proof of a harmful interaction [10].
- **Renal, cardiovascular, and psychiatric context:** pre-existing disease and concurrent medicines can complicate attribution of adverse events. The renal deterioration and suicidal ideation reports warrant attention in experimental use; neither has a quantified incidence attributable to ARA-290 [5,6].

Side Effects

- **Hematologic effects:** small human studies found no erythropoietic signal over their observed treatment periods [3,4,5,6]. Given the peptide's design and consistent short-term findings, continued absence of EPO-like red-cell stimulation is likely at comparable exposures [1,2,3,4,5,6]. This inference does not establish freedom from thrombosis or all cardiovascular risk.
- **Common adverse effects:** events such as injection-site pain, headache, fatigue, nausea, and diarrhea occurred in the dose-ranging study without a clear dose-related pattern [6]. Short-term tolerability was generally favorable, but uncommon or delayed harms were not adequately assessed [3,4,5,6,10].
- **Serious events:** the diabetes trial reported four serious adverse events in the active arm, two judged possibly related, including renal deterioration after a furosemide increase. A fatal myocardial infarction following cellulitis was judged unrelated [5]. The sarcoidosis dose-ranging trial reported serious suicidal ideation in an 8 mg participant, judged possibly related [6]. These are safety signals with uncertain causality, not proof that ARA-290 caused each event.
- **Hepatic and renal outcomes:** short-term clinical chemistry findings were generally reassuring at studied exposures [3,4,5,6]. Continued hepatic tolerability is plausible, but prolonged human exposure has not been adequately monitored. Renal reassurance is weaker because of the confounded deterioration report; a low cumulative renal risk cannot presently be inferred with confidence [5].
- **Cardiovascular and metabolic outcomes:** favorable cardiac function during prolonged treatment in aging rats supports a plausible protective effect [13]. It does not establish low

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

human arrhythmic, thrombotic, or ischemic risk. Preliminary glycemic improvements are efficacy observations, not comprehensive endocrine safety evidence [5,8].

- **Neurological and immunological outcomes:** absence of detected antibodies over short trials is reassuring within those observations [5,10]. Persistent low immunogenicity remains plausible, rather than established. The psychiatric serious event prevents an unqualified neurological safety claim, and infection risk during chronic immune modulation is insufficiently characterized [6].
- **Reproductive and proliferative outcomes:** no adequate compound-specific human evidence establishes fertility, pregnancy, or long-latency cancer safety. The available clinical trials and aging-rat functional study cannot confidently exclude these outcomes [3,4,5,6,10,13].

ARA-290 and Healthspan

The healthspan rationale rests on tissue repair, inflammatory regulation, and preservation of function. IRR expression is described as stress-responsive, and experimental signaling can suppress inflammatory pathways and support cell survival [1,2]. This creates a plausible rationale for protecting vulnerable tissues, but it does not show that every aging tissue is exposed sufficiently or responds beneficially to an intermittent human schedule.

Human neuropathy trials provide repair signals, rather than proof of general neuronal preservation during aging [3,4,5,6]. In diabetic rats and isolated islets, ARA290 enhanced glucose-stimulated insulin secretion, with evidence involving glucose metabolism, calcium entry, and the insulin-secretory pathway [8]. These findings support a mechanistic metabolic rationale without establishing human β -cell preservation. Spinal microglial effects and monocyte effects in Alzheimer-like pathology arise from distinct animal experiments and should not be conflated [11,14].

A randomized aging-rat study followed chronic treatment for up to 15 months, beginning at 18 months of age. Cardiac inflammation, age-related functional decline, and frailty were reduced, with evidence of improved autophagy and mitochondrial resistance to oxidant stress. Cardiac fibrosis was not reduced and overall survival did not differ significantly [13]. This is directly relevant preclinical healthspan evidence, but does not demonstrate human rejuvenation or validate the proposed 4/2/2 mg schedule.

A human healthspan benefit is plausible because mechanistic, disease-model, and aging-animal findings converge on tissue preservation [1,2,8,13,14]. The breadth of those findings supports investigation, but differences in exposure, disease state, endpoints, and replication prevent a probable classification for general human healthspan extension or for the specific proposed schedule.

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

Drivers of Diminished Response and Mitigation Strategies

Receptor desensitization and downstream adaptation with prolonged ARA-290 exposure have not been adequately characterized. Several features are relevant, but none independently establishes a low risk of diminished response:

- **Transient receptor-associated signaling can initiate downstream effects [1,2].**
- **Human plasma exposure is brief after SC administration [5].**
- **Some animal effects persist after a short treatment course, whereas clinical structural effects are not uniformly sustained after treatment stops [6,7,14].**

These observations do not demonstrate resistance to desensitization or establish a cycling strategy. No anti-ARA-290 antibodies were detected in the cited short human studies, including the 12-week eye study [5,10]. Longer exposure could still produce immunogenicity or biological adaptation; neither has been excluded.

Applicability for Subjects with Cushing's Disease (Speculative)

ARA-290's tissue-protective biology provides a hypothesis for selected complications in Cushing's disease, but no direct clinical evidence establishes benefit in this population [1,2,12]. Any proposed effect on nerve injury or tissue repair is speculative and should be separated from treatment of cortisol excess.

Cushing's disease causes endocrine and metabolic dysfunction, with important muscle, bone, cardiovascular, thrombotic, and infection consequences [12]. IRR-associated survival and inflammatory signaling offers a mechanistic rationale for investigation, but neuropathy trials in sarcoidosis or diabetes do not establish efficacy in hypercortisolism [2,3,4,5,6].

Potentially Relevant Cushing-related Targets

- **Neuropathic symptoms:** human neuropathy findings make a repair effect biologically plausible if a patient has independently established nerve injury [3,4,5,6]. They do not establish small-fiber neuropathy as a routine manifestation of Cushing's disease or demonstrate benefit in that disease.
- **Microvascular dysfunction and impaired repair:** experimental tissue-protection findings provide a hypothesis, but no direct evidence establishes benefit in hypercortisolism [1,2,12].
- **Immune dysregulation:** anti-inflammatory effects in other experimental settings cannot be assumed to restore immunity in cortisol excess, where infection susceptibility is clinically important [2,9,12].

Reasons the Extrapolation May Fail

- **Different disease drivers:** chronic glucocorticoid excess produces broad endocrine, metabolic, and catabolic effects [12]. ARA-290 has not been shown to correct cortisol excess, reverse its underlying cause, or replace disease-specific treatment.

*This document provides educational summaries of limited and evolving peptide data.
Nothing here is medical advice for diagnosis or treatment. © 2026 Researcher6076*

*Updated:
17-Oct-26*

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

- **Immune complexity:** a favorable inflammatory response in one model does not establish improved host defense in Cushing's disease. Disease-specific infection risk remains relevant regardless of the proposed repair mechanism [2,12].

Practical considerations and safety

- **Evidence stage:** neuropathy findings do not establish efficacy or safety in Cushing's disease, and no validated regimen exists for this application [3,4,5,6,12].
- **Monitoring and interactions:** established cardiometabolic, thrombotic, and infection risks require disease-specific management [12]. Interactions between ARA-290 and Cushing's therapies have not been established.

Biological Mechanism

ARA-290 is the pyroglutamyl helix-B surface peptide, with sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser [1,3]. It was designed to reproduce EPO-associated tissue protection without activating the erythropoietic pathway. Its proposed IRR target is an EPOR/CD131 complex, with downstream JAK/STAT and PI3K/Akt-associated survival signaling described in the tissue-protection model [1,2]. Dependence on the β -common receptor in nerve-injury experiments supports this mechanism, but does not establish receptor occupancy in every human tissue [7].

Cell and animal findings include altered inflammatory responses, cell survival, and nerve repair [1,8,9,14]. The original autoimmune-neuritis paper has a published correction, which should accompany interpretation of its experimental results [15]. Mechanistic selectivity supports specific inferences, particularly lack of erythropoiesis, but cannot by itself establish clinical benefit or comprehensive long-term safety [1,2,3,4,5,6].

References

- [1] Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. *Proc Natl Acad Sci U S A*. 2008;105(31):10925-10930. [doi:10.1073/pnas.0805594105](https://doi.org/10.1073/pnas.0805594105)
- [2] Brines M, Cerami A. The receptor that tames the innate immune response. *Mol Med*. 2012;18:486-496. [doi:10.2119/molmed.2011.00414](https://doi.org/10.2119/molmed.2011.00414)
- [3] Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. *Mol Med*. 2012;18:1430-1436. [doi:10.2119/molmed.2012.00332](https://doi.org/10.2119/molmed.2012.00332)
- [4] Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. *Mol Med*. 2013;19:334-345. [doi:10.2119/molmed.2013.00122](https://doi.org/10.2119/molmed.2013.00122)

ARA-290 (Cibinetide)

Neuropathy 4 mg SC daily for 28 days; Healthspan 4/2/2 mg SC Mon/Wed/Fri

- [5] Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Mol Med*. 2015;20:658-666. [doi:10.2119/molmed.2014.00215](https://doi.org/10.2119/molmed.2014.00215)
- [6] Culver DA, Dahan A, Bajorunas D, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. *Invest Ophthalmol Vis Sci*. 2017;58(6):BIO52-BIO60. [doi:10.1167/iovs.16-21291](https://doi.org/10.1167/iovs.16-21291)
- [7] Swartjes M, Morariu A, Niesters M, et al. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β -common receptor knockout mice. *Anesthesiology*. 2011;115(5):1084-1092. [doi:10.1097/ALN.0b013e31822fcefcd](https://doi.org/10.1097/ALN.0b013e31822fcefcd)
- [8] Muller C, Yassin K, Li LS, et al. ARA290 improves insulin release and glucose tolerance in type 2 diabetic Goto-Kakizaki rats. *Mol Med*. 2016;21(1):969-978. [doi:10.2119/molmed.2015.00267](https://doi.org/10.2119/molmed.2015.00267)
- [9] Liu Y, Luo B, Han F, et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. *PLoS One*. 2014;9(3):e90942. [doi:10.1371/journal.pone.0090942](https://doi.org/10.1371/journal.pone.0090942)
- [10] Lois N, Gardner E, McFarland M, et al. A phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema. *J Clin Med*. 2020;9(7):2225. [doi:10.3390/jcm9072225](https://doi.org/10.3390/jcm9072225)
- [11] Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, Rivest S, ElAli A. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. *Brain Behav Immun*. 2022;99:363-382. [doi:10.1016/j.bbi.2021.07.016](https://doi.org/10.1016/j.bbi.2021.07.016)
- [12] Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol*. 2021;9(12):847-875. [doi:10.1016/S2213-8587\(21\)00235-7](https://doi.org/10.1016/S2213-8587(21)00235-7)
- [13] Winicki NM, Nanavati AP, Morrell CH, et al. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan. *Front Cardiovasc Med*. 2023;9:1096887. [doi:10.3389/fcvm.2022.1096887](https://doi.org/10.3389/fcvm.2022.1096887)
- [14] Swartjes M, van Velzen M, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. *Mol Pain*. 2014;10:13. [doi:10.1186/1744-8069-10-13](https://doi.org/10.1186/1744-8069-10-13)
- [15] The PLOS ONE Staff. Correction: Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis by Inflammation Suppression and Tissue Protection. *PLoS One*. 2014;9(5):e99555. [doi:10.1371/journal.pone.0099555](https://doi.org/10.1371/journal.pone.0099555)